CordenPharma completes HPAPI laboratory expansion

Published: 19-Oct-2020
Manufacturing Finance Estates & Facilities

The laboratory is capable of handling highly potent compounds with an OEL as low as 1 ng/m3, and is already available to customers

CordenPharma has announced the completion of a highly potent API laboratory in its Boulder, Colorado facility.

CordenPharma says it has extensive experience and capabilities in the development and manufacturing of highly potent APIs from clinical to commercial scale. “Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, Director of CordenPharma’s Global Highly Potent & Oncology Platform.

  • Companies:
  • CordenPharma
See more

You may also like

Manufacturing

CordenPharma commences a €900m peptide platform expansion in the US & Europe

Read more
The expansion of CordenPharma's peptide manufacturing capabilities will serve the GLP-1 agonist market in the US, while offering end-to-end peptide manufacturing solutions in Europe

Trending Articles

  1. IMA Life and RheaVita team up to commercialise continuous biopharmaceutical freeze-drying tech The companies will work in tandem to develop and commercialise its continuous freeze-drying technology, allowing the rapid production of complex biopharmaceuticals
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  4. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation
  5. Adragos Pharma enhances its sterile injectable production capabilities with new €13m ampoule filling line The novel line at the CDMO's Livron-sur-Drôme site in France will allow the company to manufacture more than 160 million ampoules for sterile injectables annually

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Manufacturing

CordenPharma commences a €900m peptide platform expansion in the US & Europe

The expansion of CordenPharma's peptide manufacturing capabilities will serve the GLP-1 agonist market in the US, while offering end-to-end peptide manufacturing solutions in Europe
Manufacturing

Wacker and CordenPharma expand vaccine production capacity, enhancing ‘pandemic readiness’

The expansion follows an initiative the German government have launched to be 'pandemic ready', and boosts the duo's mRNA vaccine manufacturing capabilities
Manufacturing

CordenPharma and Certest partner to showcase the potential of ionisable lipids in LNP formulation

The agreement gives CordenPharma access to Certest's ionisable lipids platform, extending the company's ability to assist with the discovery, development and manufacturing of xRNA and xDNA
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Design & Build

CordenPharma expands early clinical peptide manufacturing offering

CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers
Manufacturing

CordenPharma launches lipid nanoparticle starter kits

The kits will aid in loss mitigation of high-value payloads during the gene editing journey to market
Manufacturing

CPHI Barcelona Snapshot: CordenPharma

At CPHI Barcelona, Dr Kevin Robinson talked to Dr Michael Quirmbach, CEO and President of CordenPharma, about the company’s recent activities and what lies ahead
Subscribe now